This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristindalfopristin, which may occur more frequently than has been previously reported.
adverse events prompted us to retrospectively review our experience with the use of quinupristin-dalfopristin. The primary objectives of this study were to evaluate the frequency, duration, and severity of arthralgias and/or myalgias associated with quinupristin-dalfopristin administration in a tertiary medical center, and to determine the possible risk factors associated with the development of arthralgias and/or myalgias.
Patients and methods. Records of all hospitalized pediatric and adult patients who received quinupristin-dalfopristin as treatment for any condition were reviewed. We evaluated such treatment during a 7-year period (1993) (1994) (1995) (1996) (1997) (1998) (1999) when the drug was available as an investigational compound in the United States. All patients received iv quinupristin-dalfopristin q8h for the duration of therapy. For most patients (91%), therapy was initiated at a dose of 7.5 mg/kg, unless a dose reduction (to 5 mg/kg) was necessary because of organ dysfunction or an adverse event. "Arthralgia" was defined as pain present in a joint and "myalgia" was defined as pain present in a muscle; the pain had to have been associated with quinupristin-dalfopristin administration in the absence of other identifiable causes. Case patients were patients who received quinupristin-dalfopristin treatment and who developed arthralgias and/or myalgias. Control patients were patients who received quinupristin-dalfopristin treatment but who did not develop arthralgias and/or myalgias.
The severity of each adverse event was prospectively defined as "mild," "moderate," or "severe." "Mild cases" were defined as cases of joint and/or muscle pain that were relieved with nonnarcotic interventions (e.g., heating pads, nonnarcotic analgesics, etc.) and that spontaneously resolved without dose reduction. "Moderate cases" were defined as cases of joint and/ or muscle pain that required narcotic intervention and dose reduction; the severity of this pain decreased after dose reduction. "Severe cases" were defined as cases of diffuse muscle and/ or joint pain that were not relieved by means of narcotic analgesics or dose reduction and that did not resolve until after cessation of therapy.
Data for each patient were collected from the time of initiation of quinupristin-dalfopristin treatment until the time of hospital discharge or death. Information on characteristics and potential risk factors for both case patients and control patients included the following: age; sex; WBC count; aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and serum creatinine levels; total and direct bilirubin levels; presence of an immunocompromised state (i.e., liver or stem cell transplantation); duration of therapy; body weight at study initiation; primary site of infection; microbiological etiology of infection; and duration of hospitalization. The time from initiation of quinupristin-dalfopristin therapy to the onset of arthralgias and/or myalgias was recorded, as was the duration of arthralgias and/or myalgias.
Collected data were analyzed by use of SPSS software, version 8.0 (SPSS). Data are presented as means ‫ע‬ SDs, for continuous variables, and as medians (ranges), for nonparametric data. Independent t tests (2-tailed) were used for continuous data analysis; Mann-Whitney U tests were used for analysis of nonparametric data. The significance of observed differences between case patients and control patients was analyzed by use x 2 and 2-tailed Fisher's exact tests for ordinal data. A P value of !.05 was considered significant.
Results. Fifteen (47%) of 32 patients treated with quinupristin-dalfopristin had arthralgias and/or myalgias during the study period; however, 3 control patients were unresponsive and thus were excluded from further analysis. Therefore, the total number of evaluable patients was 29 (15 case patients and 14 control patients). The characteristics of all patients who received quinupristin-dalfopristin treatment are shown in table 1. Baseline demographics were similar between case and control patients. All variables, including baseline renal and hepatic laboratory parameters, were similar for all patients who received quinupristin-dalfopristin therapy. In case patients, there was a nonsignificant trend toward higher direct bilirubin levels, in addition to increased weight, which determined the total quinupristin-dalfopristin dose that the patient received (since the drug is administered on a mg/kg basis). A comparison of baseline hepatic laboratory values with values assessed at the time of the onset of arthralgias and/or myalgias for case patients revealed no increase in transaminase or total bilirubin levels. The median direct bilirubin level increased from 2.1 mg/dL at baseline to 2.5 mg/dL (range, 0.2-26.5 mg/dL) at the time of the onset of arthralgias and/or myalgias.
Factors that related specifically to arthralgias and/or myalgias revealed that 2.8 ‫ע‬ 1.7 days was the mean time ‫ע(‬ SD) from initiation of drug therapy to the onset of adverse events that had a mean duration ‫ע(‬ SD) of 8.8 ‫ע‬ 6.8 days. Adverse events were mild in 5 case patients, moderate in 7, and severe in 3. Twelve patients had both arthralgias and myalgias. One case patient had arthralgias alone, and 2 case patients had myalgias alone. Patients who had moderate and severe arthralgias and/ or myalgias received treatment with narcotic analgesics, and their quinupristin-dalfopristin doses were concurrently reduced, such that the actual effects, if any, of the narcotic agents were possibly masked by dose decreases that resulted in a reduction in the severity of the adverse events. All incidences of arthralgias and myalgias resolved when therapy with quinupristin-dalfopristin was ceased.
Discussion. To our knowledge, this is the first investigation to report a high incidence of systemic adverse events (i.e., arthralgias and/or myalgias) that were associated with the administration of quinupristin-dalfopristin. Arthralgias and/or myalgias occurred in at least 47% of patients who received quinupristin-dalfopristin treatment after they were admitted to a single tertiary medical center. In prior noncomparative studies of the emergency use of quinupristin-dalfopristin, the percentage of patients with arthralgias and/or myalgias, regardless of whether the patients received quinupristin-dalfopristin (156 [13%] of 1199), was higher than that in comparative trials (14 [1.3%] of 1099) [7, 8] .
Vancomycin-resistant enterococci are a common microbiological etiology of infection in patients who receive treatment with quinupristin-dalfopristin; they accounted for 27 (84%) of 32 infections in the present study. Vancomycin-resistant enterococci are known to cause a significant number of nosocomial infections in transplant patients, patients with neutropenia, and other patients with impaired host defenses [9] . Many of the patients included in this study were immunocompromised (i.e., liver or stem cell transplant patients) and were considered severely ill because of their underlying medical conditions. In the present study, arthralgias and/or myalgias occurred in 9 (64%) of 14 liver transplant recipients and 6 (33%) of 18 patients who did not undergo liver transplantation but who received treatment with quinupristin-dalfopristin ( ). We found that arthralgias and/or myalgias occurred P p .15 within the first 3 days of quinupristin-dalfopristin treatment, whereas other investigators found that the risk of these events was high through treatment day 5 or 6 [8] , which suggests that most patients develop arthralgias and/or myalgias within the first week of therapy.
Quinupristin-dalfopristin has been evaluated as a treatment of infections due to antimicrobial-resistant pathogens in seriously ill groups of patients [7, 8] . Similar to patients in the present investigation, patients in a study of the emergency use of quinupristin-dalfopristin were generally quite ill with severe underlying conditions, such as leukemia, or they had undergone transplantation, or had underlying oncological disorders [7] . In open-label, noncomparative studies of the emergency use of quinupristin-dalfopristin, arthralgias and myalgias were the most common systemic adverse events, having occurred in 9.1% and 6.6% of patients, respectively [7] . Some researchers may contend that the 47% incidence in the present investigation is due to the predominance of immunocompromised patients that we studied. These patients may not have been represented as prominently in earlier clinical trials; they also may have been more likely to develop adverse events due to alterations in immune function. However, these patients are more likely to require quinupristin-dalfopristin therapy for serious infections due to antimicrobial-resistant gram-positive pathogens.
The incidence of arthralgias and/or myalgias associated with the administration of quinupristin-dalfopristin may be underreported for several reasons. First, because the severity of arthralgias and/or myalgias may be mild and may not require dose adjustments or treatment with narcotic analgesics, some investigators in phase 3 studies may have chosen not to report these as serious adverse events. It is also possible that some patients did not report muscle and/or joint pain because they did not realize it was related to the medication. In addition, as the side effect profile of quinupristin-dalfopristin became better defined, some investigators may not have reported incidences of arthralgias and/or myalgias because the revised reporting guidelines emphasized the recording of serious life-threatening and unexpected adverse events. The actual percentage of patients who had arthralgias and/or myalgias in the current investigation may be higher than we report, because 3 control patients were unresponsive and were unable to communicate any potential adverse events (including arthralgias and/or myalgias). Because of the uncertainty as to whether they had arthralgias and/or myalgias, they were not excluded from the analysis, and a minimum frequency of arthralgias and/or myalgias of 47% is reported.
The pathogenesis of arthralgias and myalgias related to the administration of quinupristin-dalfopristin is currently unknown. Quinupristin-dalfopristin is conjugated in the liver and excreted in the bile. Underlying hepatic dysfunction may potentially result in increased plasma concentrations of quinupristin-dalfopristin. Elevated total and conjugated bilirubin levels have been documented with regard to the administration of quinupristin-dalfopristin, but these elevations are usually not accompanied by increases in hepatic transaminase values [7] . Rubenstein et al. [8] suggested that increases in conjugated bilirubin levels greater than 5 times the normal are associated with quinupristin-dalfopristin administration and may be the result of competition between quinupristin-dalfopristin and bilirubin. Because of hepatic metabolism and excretion, we initially hypothesized that arthralgias and/or myalgias may be related to underlying liver dysfunction. Our data suggest, however, that these adverse events may not be related to liver dysfunction, because both case and control patients had similar baseline laboratory values, and because there were no significant increases in hepatic transaminase or total bilirubin levels at the onset of arthralgias and/or myalgias in case patients. However, baseline data from our study indicate that direct bilirubin levels were greater in case patients than in control patients, but this difference was not statistically significant.
It has recently been suggested that in patients with cases of severe or protracted arthralgias and/or myalgias, either a decrease in dose (7.5 mg/kg to 5 mg/kg) or a switch to a regimen administered q12h should be considered if the patient's infection is responding satisfactorily [8] . Administration of nonnarcotic analgesics and narcotic intervention may be beneficial for patients with mild and moderate cases, respectively, to reduce severity of the adverse event.
This investigation suggests that a significant number of patients who receive quinupristin-dalfopristin treatment may have arthralgias and/or myalgias. These findings should further alert clinicians to the potential for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Additional study is warranted to determine the mechanism of ar-
